Related Experiment Video
Updated: Jul 14, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate cancer tissue is masked by bicalutamide: a case report
J Ellinger1, P J Bastian, K Biermann
1Klinik und Poliklinik für Urologie, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany. joerg.ellinger@ukb.uni-bonn.de
European Journal of Medical Research
|May 22, 2007
Summary
Bicalutamide treatment may mask prostate cancer cells, leading to undetected residual disease after surgery. This case highlights the potential for anti-androgen therapy to obscure cancer, impacting accurate diagnosis and treatment effectiveness.
Area of Science:
- Oncology
- Urology
- Cancer Research
Background:
- Prostate cancer is a leading malignancy in men.
- Neoadjuvant anti-androgen therapies like bicalutamide aim to reduce tumor size before surgery.
- Previous studies noted decreased margin positivity with anti-androgens, but without improved patient outcomes.
Observation:
- A patient with locally recurrent prostate adenocarcinoma, five years post-prostatectomy, was treated with bicalutamide.
- Following one month of 50 mg bicalutamide therapy, the tumor was surgically resected.
- Post-resection histological examination, including immunohistochemistry, revealed no cancer-suspicious lesions.
Findings:
- Despite clinical recurrence, extensive pathological analysis of the resected tumor after bicalutamide treatment showed no evidence of cancer.
- This suggests that bicalutamide may have a 'masking' effect on prostate cancer cells, rendering them undetectable by standard histological methods.
Implications:
- Bicalutamide's potential to mask prostate cancer cells necessitates careful consideration in treatment and follow-up strategies.
- Further research is required to understand the mechanisms behind this masking effect and its clinical significance.
- This finding may prompt re-evaluation of diagnostic and therapeutic protocols involving neoadjuvant anti-androgen therapy for prostate cancer.
